Bayer’s (BAYN) “Buy” Rating Reaffirmed at DZ Bank
A number of other analysts have also weighed in on the company. Nord/LB set a €102.00 ($121.43) price objective on Bayer and gave the company a neutral rating in a research note on Friday. Citigroup reissued a buy rating on shares of Bayer in a research note on Thursday, December 7th. UBS set a €125.00 ($148.81) price objective on Bayer and gave the company a buy rating in a research note on Thursday, December 7th. Barclays set a €100.00 ($119.05) price objective on Bayer and gave the company a sell rating in a research note on Wednesday, December 6th. Finally, Berenberg Bank set a €124.00 ($147.62) price objective on Bayer and gave the company a neutral rating in a research note on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of €122.19 ($145.46).
Bayer (FRA:BAYN) opened at €105.40 ($125.48) on Monday. Bayer has a 1-year low of €93.07 ($110.80) and a 1-year high of €123.82 ($147.40).
ILLEGAL ACTIVITY WARNING: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/bayers-bayn-buy-rating-reaffirmed-at-dz-bank/1758903.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with Analyst Ratings Network's FREE daily email newsletter.